Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

AstraZeneca (AZN) is identified as a top growth stock, currently holding a Zacks Rank #3 (Hold) with strong B ratings for both its VGM and Growth Style Scores. The biopharmaceutical company is projected to achieve 11.4% year-over-year earnings growth for the current fiscal year, bolstered by recent upward revisions to its fiscal 2025 earnings estimates by analysts, increasing the Zacks Consensus Estimate to $4.58 per share. With an average earnings surprise of +3.8%, AZN's solid growth prospects and favorable Zacks scores position it as a compelling consideration for growth-oriented investors.

Analysis

AstraZeneca (AZN), a prominent global biopharmaceutical company with diverse therapeutic classes including Oncology and Rare Diseases, currently holds a Zacks Rank #3 (Hold). Despite this intermediate rank, the company demonstrates strong growth potential, reflected in its B ratings for both the overall VGM Score and the specific Growth Style Score. This indicates a favorable assessment of its fundamental growth characteristics.

The company is projected to achieve a significant 11.4% year-over-year earnings growth for the current fiscal year. This positive outlook is further supported by recent analyst activity, with three analysts revising their fiscal 2025 earnings estimates higher in the last 60 days, elevating the Zacks Consensus Estimate by $0.03 to $4.58 per share.

AZN also consistently surpasses expectations, boasting an average earnings surprise of +3.8%. These robust growth metrics, combined with positive analyst sentiment and a track record of earnings beats, position AstraZeneca as a compelling candidate for growth-focused investors. The article explicitly suggests AZN should be on investors' short list, highlighting its solid Zacks Rank and top-tier Growth and VGM Style Scores as key drivers.

Key Decisions for Investors

• Investors should consider adding AstraZeneca (AZN) to their growth-oriented watchlists, supported by its B ratings for Growth and VGM Style Scores and projected 11.4% year-over-year earnings growth.
• Monitor future Zacks Rank updates for AZN, as an upgrade from its current #3 (Hold) could signal increased short-term upside potential, especially given its strong underlying growth metrics.
• Evaluate the consistency of AZN's positive earnings surprises and continued upward analyst estimate revisions as key indicators of sustained fundamental strength and potential for long-term capital appreciation.